Kyowa Kirin to acquire Orchard Therapeutics for $478 mln
05/10/2023 09:31
TOKYO, Oct 5 (Reuters) - Japanese pharmaceutical firm
Kyowa Kirin 4151.T said on Thursday it would acquire
Britain-based biopharmaceutical company Orchard Therapeutics for
$477.6 million, aiming to promote the development of new drugs.
Kyowa said the acquisition has already been cleared by the
two firms' boards of directors but requires approval by the
British company's shareholders. It expects the deal to be
completed in the first quarter of 2024.
(Reporting by Kiyoshi Takenaka; Editing by Edmund Klamann)
((kiyoshi.takenaka@thomsonreuters.com; +81 3 4563 2788;))
Recent news on Orchard Therapeutics
See all newsBrief: Orchard Therapeutics Says Court Of Justice Of England & Wales Sanctioned Scheme Of Arrangement Providing For Acquisition Of Co By Kyowa Kirin Co's Unit
Brief: Orchard Therapeutics Receives U.S. FDA Fast Track Designation For OTL-203 In MPS-IH
Brief: Orchard Therapeutics Says U.S. FDA Advised Co It Does Not Intend To Schedule Advisory Committee Meeting
Orchard Therapeutics rises on buyout deal by Japanese drugmaker
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln